Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis.

Koot M, van Leeuwen R, de Goede RE, Keet IP, Danner S, Eeftinck Schattenkerk JK, Reiss P, Tersmette M, Lange JM, Schuitemaker H.

J Infect Dis. 1999 Jan;179(1):254-8.

PMID:
9841850
2.
3.

Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS.

Koot M, Keet IP, Vos AH, de Goede RE, Roos MT, Coutinho RA, Miedema F, Schellekens PT, Tersmette M.

Ann Intern Med. 1993 May 1;118(9):681-8.

PMID:
8096374
4.

Phenotype-associated env gene variation among eight related human immunodeficiency virus type 1 clones: evidence for in vivo recombination and determinants of cytotropism outside the V3 domain.

Groenink M, Andeweg AC, Fouchier RA, Broersen S, van der Jagt RC, Schuitemaker H, de Goede RE, Bosch ML, Huisman HG, Tersmette M.

J Virol. 1992 Oct;66(10):6175-80.

5.

Genetic and functional analysis of a set of HIV-1 envelope genes obtained from biological clones with varying syncytium-inducing capacities.

Andeweg AC, Groenink M, Leeflang P, de Goede RE, Osterhaus AD, Tersmette M, Bosch ML.

AIDS Res Hum Retroviruses. 1992 Oct;8(10):1803-13.

PMID:
1457193
6.

Concordance of human immunodeficiency virus detection by polymerase chain reaction and by serologic assays in a Dutch cohort of seronegative homosexual men.

Bruisten SM, Koppelman MH, Dekker JT, Bakker M, de Goede RE, Roos MT, de Wolf F, Coutinho RA, Goudsmit J, Huisman HG.

J Infect Dis. 1992 Sep;166(3):620-2.

PMID:
1500745
7.

Differential tropism of clinical HIV-1 isolates for primary monocytes and promonocytic cell lines.

Schuitemaker H, Kootstra NA, Groenink M, De Goede RE, Miedema F, Tersmette M.

AIDS Res Hum Retroviruses. 1992 Sep;8(9):1679-82.

PMID:
1457212
8.

Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population.

Schuitemaker H, Koot M, Kootstra NA, Dercksen MW, de Goede RE, van Steenwijk RP, Lange JM, Schattenkerk JK, Miedema F, Tersmette M.

J Virol. 1992 Mar;66(3):1354-60.

9.

Viral phenotype and immune response in primary human immunodeficiency virus type 1 infection.

Roos MT, Lange JM, de Goede RE, Coutinho RA, Schellekens PT, Miedema F, Tersmette M.

J Infect Dis. 1992 Mar;165(3):427-32.

PMID:
1347054
10.

HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay.

Koot M, Vos AH, Keet RP, de Goede RE, Dercksen MW, Terpstra FG, Coutinho RA, Miedema F, Tersmette M.

AIDS. 1992 Jan;6(1):49-54.

PMID:
1543566
11.

Immunological and virological markers in individuals progressing from seroconversion to AIDS.

Gruters RA, Terpstra FG, De Goede RE, Mulder JW, De Wolf F, Schellekens PT, Van Lier RA, Tersmette M, Miedema F.

AIDS. 1991 Jul;5(7):837-44.

PMID:
1892588
12.

Phenotypic heterogeneity in a panel of infectious molecular human immunodeficiency virus type 1 clones derived from a single individual.

Groenink M, Fouchier RA, de Goede RE, de Wolf F, Gruters RA, Cuypers HT, Huisman HG, Tersmette M.

J Virol. 1991 Apr;65(4):1968-75.

14.

Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy.

Boucher CA, Tersmette M, Lange JM, Kellam P, de Goede RE, Mulder JW, Darby G, Goudsmit J, Larder BA.

Lancet. 1990 Sep 8;336(8715):585-90.

PMID:
1975378
15.

Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality.

Tersmette M, Lange JM, de Goede RE, de Wolf F, Eeftink-Schattenkerk JK, Schellekens PT, Coutinho RA, Huisman JG, Goudsmit J, Miedema F.

Lancet. 1989 May 6;1(8645):983-5.

PMID:
2565516
16.

Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates.

Tersmette M, Gruters RA, de Wolf F, de Goede RE, Lange JM, Schellekens PT, Goudsmit J, Huisman HG, Miedema F.

J Virol. 1989 May;63(5):2118-25.

17.

Human immunodeficiency virus infection studied in CD4-expressing human-murine T-cell hybrids.

Tersmette M, van Dongen JJ, Clapham PR, de Goede RE, Wolvers-Tettero IL, Geurts van Kessel A, Huisman JG, Weiss RA, Miedema F.

Virology. 1989 Feb;168(2):267-73.

PMID:
2464872
18.

Major histocompatibility complex class II-regulated immunity to murine leukemia virus protects against early T- but not late B-cell lymphomas.

Vasmel WL, Zijlstra M, Radaszkiewicz T, Leupers CJ, de Goede RE, Melief CJ.

J Virol. 1988 Sep;62(9):3156-66.

20.

Decreased accessory cell function by human monocytic cells after infection with HIV.

Petit AJ, Tersmette M, Terpstra FG, de Goede RE, van Lier RA, Miedema F.

J Immunol. 1988 Mar 1;140(5):1485-9.

PMID:
2964477
21.

Confirmation of HIV seropositivity: comparison of a novel radioimmunoprecipitation assay to immunoblotting and virus culture.

Tersmette M, Lelie PN, van der Poel CL, Wester MR, de Goede RE, Lange JM, Miedema F, Huisman JG.

J Med Virol. 1988 Jan;24(1):109-16.

PMID:
2828529
22.

Interference with HIV-induced syncytium formation and viral infectivity by inhibitors of trimming glucosidase.

Gruters RA, Neefjes JJ, Tersmette M, de Goede RE, Tulp A, Huisman HG, Miedema F, Ploegh HL.

Nature. 1987 Nov 5-11;330(6143):74-7.

PMID:
2959866
23.

Tumor progression in murine leukemia virus-induced T-cell lymphomas: monitoring clonal selections with viral and cellular probes.

Cuypers HT, Selten GC, Zijlstra M, de Goede RE, Melief CJ, Berns AJ.

J Virol. 1986 Oct;60(1):230-41.

24.

Imbalanced MHC class II molecule expression at surface of murine B cell lymphomas.

Zijlstra M, Vasmel WL, Voormanns M, de Goede RE, Schoenmakers HJ, Nieland J, Slater RM, Melief CJ.

J Exp Med. 1986 May 1;163(5):1213-26.

25.

Thermal inactivation of human immunodeficiency virus in lyophilised blood products evaluated by ID50 titrations.

Tersmette M, de Goede RE, Over J, de Jonge E, Radema H, Lucas CJ, Huisman HG, Miedema F.

Vox Sang. 1986;51(3):239-43.

PMID:
3643679
26.

Ecotropic and dualtropic mink cell focus-inducing murine leukemia viruses can induce a wide spectrum of H-2 controlled lymphoma types.

Zijlstra M, de Goede RE, Schoenmakers H, Radaszkiewicz T, Melief CJ.

Virology. 1984 Oct 30;138(2):198-211.

PMID:
6333756
27.

H-2 control of the cytotoxic antibody response against a newly defined MuLV-related cell-surface antigen: G(B10.A).

Vlug A, Zijlstra M, de Goede RE, Hesselink WG, Schoenmakers HJ, Melief CJ.

Int J Cancer. 1983 May 15;31(5):617-26.

PMID:
6303968
28.

Naturally occurring leukemia viruses in H-2 congenic C57BL mice. III. Characterization of C-type viruses isolated from lymphomas induced by milk transmission of B-ecotropic virus.

Zijlstra M, de Goede RE, Schoenmakers HJ, Schinkel AH, Hesselink WG, Portis JL, Melief CJ.

Virology. 1983 Feb;125(1):47-63.

PMID:
6187128
29.

Naturally occurring leukemia viruses in H-2 congenic C57BL mice. I. High lymphoma incidence following milk-borne transmission of virus.

Melief CJ, Vlug A, de Goede RE, de Bruyne C, Barendsen W, de Greeve P.

J Natl Cancer Inst. 1980 May;64(5):1179-89.

PMID:
6245301
30.

Antibody-dependent lymphocytotoxicity: an analysis of effector cell-target cell interactions.

van Oers MH, de Goede RE, Zeijlemaker WP.

J Immunol. 1978 Aug;121(2):499-504.

PMID:
98585
31.

Cytotoxic activity of human lymphocytes: quanitative analysis of T cell and K cell cytotoxicity, revealing enzyme-like kinetics.

Zeijlemaker WP, van Oers RH, de Goede RE, Schellekens PT.

J Immunol. 1977 Oct;119(4):1507-14. No abstract available.

PMID:
408421

Supplemental Content

Loading ...
Support Center